These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847 [TBL] [Abstract][Full Text] [Related]
3. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571 [TBL] [Abstract][Full Text] [Related]
4. Interaction between carbamazepine and bromperidol. Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Furukori H; Kaneko S; Inoue Y Eur J Clin Pharmacol; 1997; 52(3):219-22. PubMed ID: 9218929 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up. Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768 [TBL] [Abstract][Full Text] [Related]
6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346 [TBL] [Abstract][Full Text] [Related]
7. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348 [TBL] [Abstract][Full Text] [Related]
8. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses]. Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M Encephale; 1995; 21(6):417-24. PubMed ID: 8674466 [TBL] [Abstract][Full Text] [Related]
9. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Pan L; Vander Stichele R; Rosseel MT; Berlo JA; De Schepper N; Belpaire FM Ther Drug Monit; 1999 Oct; 21(5):489-97. PubMed ID: 10519444 [TBL] [Abstract][Full Text] [Related]
10. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. Ulrich S; Neuhof S; Braun V; Meyer FP Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314 [TBL] [Abstract][Full Text] [Related]
11. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. Hirokane G; Someya T; Takahashi S; Morita S; Shimoda K Ther Drug Monit; 1999 Feb; 21(1):82-6. PubMed ID: 10051058 [TBL] [Abstract][Full Text] [Related]
12. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment. Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460 [TBL] [Abstract][Full Text] [Related]